| |
We invite you to join us at the Fierce Medical Affairs Strategic Summit West. Join medical affairs, field medical, and medical communications teams to share best practices, gain actionable insights and crowdsource ideas to their unique challenges from their peers. Register now
|
|
Today's Big NewsJul 7, 2023 |
| By Angus Liu GSK's long-acting Cabenuva is currently approved only as a switch therapy for patients who already have undetectable HIV levels in the blood. Trying to reach some tough populations who have difficulty adhering to existing daily oral therapies, GSK is getting creative. |
|
|
|
By Andrea Park There’s something fishy about Coloplast’s latest megadeal—literally. The Danish medtech announced plans on Friday to acquire Kerecis, which uses fish skin as the basis of its wound care products for humans. |
By Gabrielle Masson Eli Lilly’s Prevail Therapeutics has changed up a licensing agreement with gene therapy biotech Precision Therapeutics, dropping the biobucks value and seeking a bigger share of pre-clinical duties. |
By Kevin Dunleavy In late May, the FDA warned of illegal knockoffs of Novo Nordisk’s Ozempic and Wegovy. And now, the Danish company has filed its second wave of lawsuits against pharmacies in the U.S. that are producing the copycats. |
|
Wednesday, July 12, 2023 | 2pm ET/11am PT In this webinar, we will explore how critical it is for life sciences companies to use data to analyze the behavior of cancer at the individual level, uncover new targets and biomarkers for precision therapies, and increase the value of existing oncology drugs to new indications. Register now.
|
|
By Annalee Armstrong Scientists have long known that cancer cells typically have extra chromosomes, but what exactly was the extra genetic material doing? New research from a team at Yale University has finally provided an answer. |
By Andrea Park Less than a year after it was flooded with $100 million in venture capital, and just as a new trial of its energy therapy technology ramps up, Galvanize Therapeutics is now undergoing a decidedly less exciting update. |
By Nick Paul Taylor BrainStorm Cell Therapeutics has latched on to the recent accelerated FDA approval of Biogen and Ionis’ amyotrophic lateral sclerosis (ALS) drug to make the case that its cell therapy could join the rival product on the U.S. market. |
By Zoey Becker After the FDA slammed the company's Pithampur, India, plant in a March Form 483 filing, Cipla pulled six batches of albuterol from U.S. shelves due to a complaint about a leak in one inhaler. |
By Teresa Carey This week on "The Top Line," we discuss new HIV therapies, plus Humira's new biosimilar, foreign pharmaceutical investments, and the rest of the week's headlines. |
Fierce podcastsDon't miss an episode |
| This week on "The Top Line," we discuss the American Diabetes Association's annual conference, plus a statement about transgender care, light therapy, and the rest of the week's headlines. |
|
|---|
|
|
|
Wednesday, July 12, 2023 | 11:00am ET / 8:00am PT Join us for this insightful discussion on how to unlock the full potential of liquid biopsy and be an integral part of the future of precision medicine. We’ll take a deep dive into the latest strategies and solutions designed to help overcome current challenges and empower researchers and clinicians with enhanced capabilities. Register now.
|
|
| ResearchThe right sourcing strategy can help save of millions of dollars—learn about developing a strategy for sourcing the cGMP chemicals critical to your processes. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WhitepaperLearn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
| eBookThis eBook identifies the trends driving major change in the Medical Affairs (MA) function. It also outlines the strategic and tactical implications for MA leaders and team members. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| eBookTake a look at the reporting tools sponsors need to access insights earlier in the clinical trial enrollment funnel, so you can take informed actions. Sponsored by: OneStudyTeam |
| WhitepaperLearn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| |
|
